Other News To Note
Cytovance Biologics Inc., of Oklahoma City, and Fountain BioPharma Inc., of Taiwan, executed a biopharmaceutical development and manufacturing collaboration for FB301, a monoclonal antibody under development by Fountain with a lead indication of allergic disease.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter